Tech Transfer eNews Blog

Neovii enters license agreement with Tel Aviv U to advance novel COVID-19 vaccine

By David Schwartz
Published: May 19th, 2020

Neovii, a Swiss-based biopharmaceutical company, has entered into a research and license agreement with Ramot, the tech transfer arm of Tel Aviv University (TAU), to advance a novel and potentially life-saving COVID-19 vaccine.

The licensed technology, developed by TAU professor Jonathan Gershoni, is a platform for the rapid discovery of epitope-based vaccines. Under the agreement, Neovii will collaborate with Gershoni and TAU to develop a first-in-class COVID-19 vaccine that reconstructs the coronavirus’ Receptor Binding Motif (RBM), a critical structure of its “spike” protein. By targeting the RBM, Neovii plans to go after the Achilles’ heel of the virus.

“The virus takes far-reaching measures to hide its RBM from the human immune system, but the best way to win the war is to develop a vaccine that specifically targets the virus’s RBM,” says Gershoni. “The smaller the target and the focus of the attack, the safer and greater the effectiveness of the vaccine.”

Jürgen Pohle, CEO of Neovii, comments, “We are extremely excited about our collaboration with Professor Gershoni and TAU, which provides Neovii with a first-in-class platform for the rapid development of promising vaccine candidates towards any future emerging pandemics including COVID-19. Furthermore, the COVID-19 vaccine is highly synergistic to Neovii’s core expertise in the development and manufacturing of passive polyclonal antibodies and provides an opportunity to bring a COVID-19 immunotherapy in a rapid manner.”

According to Gershoni, the vaccine could be ready for use within a year to a year and a half. Source:

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment